首页 | 本学科首页   官方微博 | 高级检索  
检索        

移植分泌神经营养素3的人胚神经干细胞在脊髓损伤大鼠体内存活及对运动功能的影响
引用本文:蔡培强,孙广运,Peishu Cai,Martin Oudeg,Rui Xiao,Xuewen Wang,Wei Li,Yunbing Shu,Cheng Cai,Haihao Yang,Xuebing Shan,Wuhua Luo.移植分泌神经营养素3的人胚神经干细胞在脊髓损伤大鼠体内存活及对运动功能的影响[J].中国神经再生研究,2009,4(7):485-491.
作者姓名:蔡培强  孙广运  Peishu Cai  Martin Oudeg  Rui Xiao  Xuewen Wang  Wei Li  Yunbing Shu  Cheng Cai  Haihao Yang  Xuebing Shan  Wuhua Luo
作者单位:宜宾市第一人民医院骨二科,宜宾市第一人民医院骨二科,Department of Orthopaedics, First People’s Hospital of Yibin, Yibin 644000, Sichuan Province, China,International Center for Spinal Cord Injury, Kennedy Krieger Institute Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA,epartment of Orthopaedics, First People’s Hospital of Yibin, Yibin 644000, Sichuan Province, China,Department of Orthopaedics, First People’s Hospital of Yibin, Yibin 644000, Sichuan Province, China,Department of Orthopaedics, First People’s Hospital of Yibin, Yibin 644000, Sichuan Province, China,Department of Orthopaedics, First People’s Hospital of Yibin, Yibin 644000, Sichuan Province, China,Department of Orthopaedics, First People’s Hospital of Yibin, Yibin 644000, Sichuan Province, China,Department of Orthopaedics, First People’s Hospital of Yibin, Yibin 644000, Sichuan Province, China,Department of Orthopaedics, First People’s Hospital of Yibin, Yibin 644000, Sichuan Province, China,Department of Orthopaedics, First People’s Hospital of Yibin, Yibin 644000, Sichuan Province, China
摘    要:BACKGROUND: Many methods have been attempted to repair nerves following spinal cord injury, including peripheral nerve transplantation, Schwann cell transplantation, olfactory ensheathing cell transplantation, and embryonic neural tissue transplantation. However, there is a need for improved outcomes.
OBJECTIVE: To investigate the repair feasibility for rat spinal cord injury using human neural stem cells (hNSCs) genetically modified by lentivirus to express neurotrophin-3.
DESIGN, TIME AND SETTING: In vitro cell biological experiment and in vivo randomized, controlled genetic engineering experiment were performed at the Third Military Medical University of Chinese PLA and First People's Hospital of Yibin, China from March 2006 to December 2007.
MATERIALS: A total of 64 adult, female, Wistar rats were used for the in vivo study. Of them, 48 rats were used to establish models of spinal cord hemisection, and were subsequently equally and randomly assigned to model, genetically modified hNSC, and normal hNSC groups. The remaining 16 rats served as normal controls.
METHODS: hNSCs were in vitro genetically modified by lentivirus to secrete both green fluorescence protein and neurotrophin-3. Neurotrophin-3 expression was measured by Western blot. Genetically modified hNSC or normal hNSC suspension (5 × 10^5) was injected into the rat spinal cord following T10 spinal cord hemisection. A total of 5μL Dulbecco's-modified Eagle's medium was infused into the rat spinal cord in the model grop. Transgene expression and survival of transplanted hNSCs were determined by immunohistochemistry. Motor function was evaluated using the Basso, Beattie, and Bresnahan (BBB) scale.
MAIN OUTCOME MEASURES: The following parameters were measured: expression of neurotrophin-3 produced by genetically modified hNSCs, transgene expression and survival of hNSCs in rats, motor function in rats.
RESULTS: hNSCs were successfully genetically modified by lentivirus to stably express neurotrophin-3. The transplanted hNSCs primarily gathered at, or around, the injection site two weeks following transplantation, and gradually migrated towards the surrounding tissue. Transplanted hNSCs were observed 7.0-8.0 mm away from the injection site. In addition, hNSCs were observed 10 weeks after transplantation. At week 4, BBB locomotor scores were significantly greater in the genetically modified hNSC and normal hNSC groups, compared with the model group (P 〈 0.05), and scores were significantly greater in the genetically modified hNSC group compared with the normal hNSC group (P 〈 0.05).
CONCLUSION: hNSCs were genetically modified with lentivirus to stably secrete neurotrophin-3. hNSCs improved motor function recovery in rats following spinal cord injury.

关 键 词:神经营养因子-3  神经干细胞  大鼠模型  脊髓损伤  运动功能  人类  移植

Survival of transplanted neurotrophin-3 expressing human neural stem cells and motor function in a rat model of spinal cord injury
Peiqiang Cai,Guangyun Sun,Peishu Cai,Martin Oudeg,Rui Xiao,Xuewen Wang,Wei Li,Yunbing Shu,Cheng Cai,Haihao Yang,Xuebing Shan and Wuhua Luo.Survival of transplanted neurotrophin-3 expressing human neural stem cells and motor function in a rat model of spinal cord injury[J].Neural Regeneration Research,2009,4(7):485-491.
Authors:Peiqiang Cai  Guangyun Sun  Peishu Cai  Martin Oudeg  Rui Xiao  Xuewen Wang  Wei Li  Yunbing Shu  Cheng Cai  Haihao Yang  Xuebing Shan and Wuhua Luo
Institution:[1]Department of Orthopaedics, First People's Hospital of Yibin, Yibin 644000, Sichuan Province, China [2]International Center for Spinal Cord Injury, Kennedy Krieger Institute Department of Neurology, Johns Hopkins University School of Medicine,Baltimore, MD 21205, USA
Abstract:BACKGROUND: Many methods have been attempted to repair nerves following spinal cord injury,including peripheral nerve transplantation, Schwann cell transplantation, olfactory ensheathing cell transplantation, and embryonic neural tissue transplantation. However, there is a need for improved outcomes.OBJECTIVE: To investigate the repair feasibility for rat spinal cord injury using human neural stem cells (hNSCs) genetically modified by lentivirus to express neurotrophin-3.DESIGN, TIME AND SETTING: In vitro cell biological experiment and in vivo randomized, controlled,genetic engineering experiment were performed at the Third Military Medical University of Chinese PLA and First People's Hospital of Yibin, China from March 2006 to December 2007.MATERIALS: A total of 64 adult, female, Wistar rats were used for the in vivo study. Of them, 48 rats were used to establish models of spinal cord hemisection, and were subsequently equally and randomly assigned to model, genetically modified hNSC, and normal hNSC groups. The remaining 16 rats served as normal controls.METHODS: hNSCs were in vitro genetically modified by lentivirus to secrete both green fluorescence protein and neurotrophin-3. Neurotrophin-3 expression was measured by Westem blot.Genetically modified hNSC or normal hNSC suspension (5×105) was injected into the rat spinal cord following T10 spinal cord hemisection. A total of 5μL Dulbecco's-modified Eagle's medium was infused into the rat spinal cord in the model group. Transgene expression and survival of transplanted hNSCs were determined by immunohistochemistry. Motor function was evaluatedusing the Basso, Beattie, and Bresnahan (BBB) scale.MAIN OUTCOME MEASURES: The following parameters were measured: expression ofneurotrophin-3 produced by genetically modified hNSCs, transgene expression and survival ofhNSCs in rats, motor function in rats.RESULTS: hNSCs were successfully genetically modified by lentivirus to stably express neurotrophin-3. The transplanted hNSCs primarily gathered at, or around, the injection site two weeks following transplantation, and gradually migrated towards the surrounding tissue.Transplanted hNSCs were observed 7.0 8.0 mm away from the injection site. In addition, hNSCs were observed 10 weeks after transplantation. At week 4, BBB locomotor scores were significantly greater in the genetically modified hNSC and normal hNSC groups, compared with the model group (P<0.05), and scores were significantly greater in the genetically modified hNSC group compared with the normal hNSC group (P<0.05).CONCLUSION: hNSCs were genetically modified with lentivirus to stably secrete neurotrophin-3.hNSCs improved motor function recovery in rats following spinal cord injury.
Keywords:lentivirus  spinal cord injury  human neural stem cells  genetic engineering  neurotrophin-3  green fluorescence protein
本文献已被 维普 万方数据 等数据库收录!
点击此处可从《中国神经再生研究》浏览原始摘要信息
点击此处可从《中国神经再生研究》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号